About CENTOGENE

CENTOGENE are experts in genetic testing and a global leader in the diagnosis of rare genetic diseases. We conform to the highest standards for diagnostic testing and reporting and hold multiple international accreditations (ISO, CAP and CLIA). CentoNIPT® is performed, analyzed and supported by CENTOGENE's team of highly experienced laboratory scientists and genetic clinicians. Worldwide, more than 350,000 individual patients from over 100 countries trust CENTOGENE.

Transforming global genetic data into medical decisions
How does non-invasive prenatal testing work?

Small amounts of a baby’s DNA pass into the bloodstream of the mother during pregnancy. New technology allows us to analyse this DNA directly from the mother’s blood and screen for chromosomal abnormalities.

Until recently it has only been possible to screen for abnormalities with highly invasive procedures such as chorionic villus sampling (CVS) or amniocentesis. These tests carry an elevated risk of miscarriage and are only performed later in pregnancy.

Initial screening with CentoNIPT® can help to avoid this potentially unnecessary and invasive testing. **There is no risk to mother or baby and CentoNIPT® provides the earliest testing available.**

CentoNIPT® - Illumina VeriSeq™ NIPT Solution v2*

Safe & accurate prenatal testing

Our DNA carries all the genetic information we require for normal health and development. It exists in our cells as 23 pairs of chromosomes. During pregnancy, chromosomal abnormalities can arise in the developing baby as a result of incorrect egg or sperm formation, or during the earliest stages of the baby’s development. These chromosomal abnormalities can significantly affect the health and well-being of a baby and it is important to identify any abnormalities as early as possible.

CentoNIPT® delivers a clear positive or negative result for chromosomal abnormalities where an extra copy of one chromosome is present (Trisomy). Down syndrome, the most common chromosomal abnormality, can be detected with an accuracy rate of >99.9%.

CentoNIPT® also screens for changes in the number of X or Y chromosomes. The test is also suitable if you are pregnant with twins.**

*Sample preparation and analysis software are CE-IVD marked
**Sex chromosomal aneuploidies cannot be detected for twin pregnancies.
WHAT DOES CentoNIPT® SCREEN FOR?

› **Down syndrome** (Trisomie 21): affects 1 in 1,000 live births
› **Edwards syndrome** (Trisomy 18): affects 1 in 3,000-6,000 live births
› **Patau syndrome** (Trisomy 13): affects 1 in every 5,000 live births

THE TEST CAN ALSO DETECT ABNORMALITIES OF THE SEX CHROMOSOMES:

› Turner syndrome (Monosomy X)
› Klinefelter syndrome (XXY)
› Jacobs syndrome (XYY)
› Triple X syndrome (XXX)

WHY SHOULD YOU CHOOSE CentoNIPT®?

› Completely safe for you and your baby
› Highest test accuracy
› Test from the 10th week of pregnancy
› Only a single blood sample required
› Results provided 5 business days of sample receipt
How is the test performed?

A single blood sample, collected by your physician, is sent to our laboratory for analysis. Test results are typically provided to your physician within 5 business days of sample receipt at CENTOGENE.

What will the results tell me?

The results will show whether any of the described chromosomal abnormalities have been detected in your baby. If the results are normal, this will provide you with the reassurance that these most common genetic abnormalities are not present. If the NIPT is positive for a chromosomal abnormality, your physician will offer you additional testing for confirmation of test results and refer you for genetic counseling to discuss the implications and choices available for you and your baby.

What are the limitations of the test?

CentoNIPT® detects the most common prenatal chromosomal abnormalities as outlined above. However, the test cannot rule out the possibility of other, less common genetic diseases. CentoNIPT® has the lowest assay failure rate of available NIPT on the market. This means the lowest risk for redraw or having to perform unnecessary invasive testing instead.
The information and views set out in this brochure are those of the author to the best of its knowledge and belief, using professional diligence. Neither the author nor CENTOGENE nor any person acting on their behalf may be held responsible for the use, interpretation, deductions, inferences, generalizations or further communication which may be made of, in connection with or as a result of the information, data and/or facts contained in this brochure. No warranty, neither expressed nor implied, is given and no legal liability or responsibility shall evolve for the accuracy, completeness or usefulness of any information, data and/or facts disclosed and shown in this brochure.

Noninvasive prenatal testing (NIPT) based on cell-free DNA analysis from maternal blood is a screening test; it is not diagnostic. Test results must not be used as the sole basis for diagnosis. Further confirmatory testing is necessary prior to making any irreversible pregnancy decision. CentoNIPT® and CENTOGENE®, any associated logos, and all associated CENTOGENE® registered or unregistered trademarks are the property of CENTOGENE AG. All third-party marks—® and ™—are the property of their respective owners. Illumina® and the Powered by Illumina™ logo are trademarks of Illumina, Inc. in the U.S. and other countries.

Please visit our website for more information:

www.centogene.com

CONTACT DETAILS:

CENTOGENE AG
Am Strande 7
18055 Rostock
Germany

CENTOGENE AG is a subsidiary of CENTOGENE N.V.

(customer.support@centogene.com)
(+49 (0)381 80 113 - 416)
(+49 (0)381 80 113 - 401)

FOR U.S PARTNERS

(customer.support-us@centogene.com)
(+1 (617) 580 - 2102)

CLIA #99D2049715
Following GLP and GMP guidelines.